This Guide applies to the manufacture of APIs for medicinal products for both human and veterinary use. It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered but should be performed in accordance with the principles and guidelines of GMP as laid down in national legislations and interpreted in the GMP Guide including its Annex 1.
The holder of a Manufacturing Authorisation must manufacture medicinal products so as to ensure that they are fit for their intended use, comply with the requirements of the Marketing Authorisation or Clinical Trial Authorisation, as appropriate, and do not place patients at risk due to inadequate safety, quality or
efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment by staff in many different departments and at all levels within the company, by the company’s suppliers, and by its distributors. To achieve this quality objective reliably there must be a comprehensively designed and correctly implemented Pharmaceutical Quality System incorporating Good Manufacturing Practice and Quality Risk Management. It should be fully documented and its effectiveness monitored. All parts of the Pharmaceutical Quality System should be adequately resourced with
competent personnel, and suitable and sufficient premises, equipment, and facilities. There are additional legal responsibilities for the holder of the Manufacturing Authorisation and for the Authorised Person(s).
This article describes following points;
This article describes following points;
The electronic application form has been prepared to be filled in by the applicant in case of an application made either by national route or by mutual recognition, decentralised or centralised procedures.
In the case of a mutual recognition or decentralised procedure an application form should be filled in for all competent authorities where the application is made.
The same applicant should apply in all concerned member states. Since some information may differ between member states (e.g. marketing authorisation holder/registration holder, legal status, contact persons etc.), the appropriate sections should be replicated where necessary.
This guideline also describes following points;
This guideline describes checklist for the transfer of PMF to a New Holder and application for a PMF 2nd Step Notification.
This guidance document therefore aims to address the specific requirements for the structure, format and presentation of an eCTD used to submit a Plasma Master File (PMF), or to present changes to a PMF within the certification procedure.
This guidance also intends to address the practical requirements for the use of the eCTD format for a 2nd step procedure after a PMF (re)certification/variation.
This article describes following points;
This article describes questions and answers on the use of Out-Of-Specification batches of authorised Cell/Tissue-Based Advanced Therapy Medicinal Products like;
The European Medicines Agency (EMA) provides guidance in the form of questions and answers (Q&As) to marketing authorisation holders of centrally authorised veterinary medicines about classification of changes to the marketing authorisation post-authorisation and certain variation classification categories.
These Q&As are for guidance only and should be read in conjunction with the rules governing medicinal products in the European Union, volume 6, notice to applicants, the European Commission ‘Variations Guidelines’ 2013/C 223/01 and the Recommendation for classification of unforeseen variations according to Article 5 of Commission Regulation (EC) 1234/2008 published on the website of coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), which covers CMDh/v and EMA human/vet
The guidance provided by the working group in the form of questions and answers (Q&As) provides additional interpretation of the European Union (EU) GMP guidelines and GDP guidelines published by the European Commission.
This guideline describes following points;